Dmitriy Niyazov is a Rare/Genetic physician affiliated with Duke University. OpenAlex indexes 14 publications with 637 citations (h-index 8).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
905 S Lasalle St
Durham, NC 277102429
Telephone
504-905-9940Provider last certified this registry record 22 Feb 2024.
Industry payments
9 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- GENZYME CORPORATIONProgram year202528 payments$32,791openpaymentsdata.cms.gov ↗
- Alexion Pharmaceuticals, Inc.Program year202541 payments$19,456openpaymentsdata.cms.gov ↗
- Sarepta Therapeutics, Inc.Program year20259 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
100%Tissue-nonspecific Alkaline Phosphatase100%Strensiq100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- P354: Vosoritide as a targeted therapy for FGFR3-related thanatophoric dysplasia
Genetics in Medicine Open
2025 - Hypotrichosis‐lymphedema‐telangiectasia syndrome: Report of ileal atresia associated with a <scp><i>SOX18</i></scp> de novo pathogenic variant and review of the phenotypic spectrum
American Journal of Medical Genetics Part A
2021 - Clinical and Molecular Characteristics of Mitochondrial Dysfunction in Autism Spectrum Disorder
Molecular Diagnosis & Therapy
2018 - Confirming TDP2 mutation in spinocerebellar ataxia autosomal recessive 23 (SCAR23)
Neurology Genetics
2018
Similar KOLs
Other experts from the same institution or the same specialty.
Robert Califf, MD
Duke University
Pamela Douglas, MD
Duke University
Adrian Hernandez, MD
Duke University
John Perfect, MD
Duke University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”